CRISPR Meets Caffeine: Scientists Develop New Approach to Cancer Treatment

Researchers at Texas A&M are pairing a widely used ingredient with advanced medical technology to develop new treatments for ...
Pharmabiz

Partner Therapeutics’ zenocutuzumab-zbco receives US FDA Orphan Drug Designation for ...

Partner Therapeutics’ zenocutuzumab-zbco receives US FDA Orphan Drug Designation for treatment of cholangiocarcinoma: Lexington, Massachusetts Saturday, February 7, 2026, 17:00 ...

Zenocutuzumab--zbco Receives FDA Orphan Drug Designation for Treatment of Cholangiocarcinoma

Zenocutuzumab--zbco, marketed as BIZENGRI (R), received Breakthrough Therapy Designation from the FDA in October 2025 and was granted accelerated approval in December 2024 for adults with advanced ...